Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02635672Phase 1Completed

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Role: lead

NCT05712889Phase 1Completed

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Role: lead

NCT06034275Phase 1Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Role: lead

NCT04978779Phase 1Terminated

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Role: lead

All 4 trials loaded